Zentalis(ZNTL) - 2025 Q4 - Annual Report

Clinical Development and Trials - Azenosertib (ZN-c3) is a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for ovarian cancer, with a focus on Cyclin E1-positive platinum-resistant ovarian cancer (PROC) [23]. - The DENALI Part 2 clinical trial aims to enroll approximately 100 patients with Cyclin E1-positive PROC, with a topline readout anticipated by the end of 2026; the trial has the potential to support accelerated approval from the FDA [26]. - In January 2025, clinical data from DENALI Part 1b showed an objective response rate (ORR) of 34.9% in response-evaluable patients with Cyclin E1-positive PROC [32]. - Azenosertib is also being evaluated in combination with bevacizumab in a Phase 1b clinical trial for ovarian cancer, with ongoing patient enrollment [30]. - The company plans to initiate a Phase 3 trial (ASPENOVA) in the first half of 2026 to compare azenosertib against standard-of-care chemotherapy for Cyclin E1-positive PROC [30]. - The median duration of response (mDOR) for the intent-to-treat population in DENALI Part 1b was approximately 6.3 months as of January 13, 2025 [35]. - A total of 193 patients were involved in the ZN-c3-001 study, with a daily dose of ≥300 mg, showing a 5.2% discontinuation rate due to treatment-related adverse events [42]. - The safety profile of azenosertib showed treatment-related serious adverse events in 21.6% of patients, with common adverse events including nausea (65.7%) and fatigue (59.8%) [33]. - Patient enrollment is critical for clinical trials, and difficulties in this area could lead to significant delays or abandonment of trials [192]. Market Opportunity and Competition - The global ovarian cancer market was approximately $3 billion in 2022, with an estimated 21,500 PROC patients in the U.S. and EU4 who overexpress Cyclin E1, indicating a significant market opportunity for azenosertib [28]. - Approximately 50% of PROC patients are estimated to overexpress Cyclin E1, highlighting the unmet need for targeted therapies in this patient population [28]. - The biotechnology and pharmaceutical industries are characterized by significant competition, with potential competitors having greater financial resources and expertise [45]. - There are currently no FDA-approved WEE1 inhibitors, but several companies are evaluating various WEE1 inhibitors in clinical trials [49]. - The company faces intense competition in oncology, with numerous established and emerging companies developing similar therapies [205]. - Competitors may develop safer, more effective products, potentially reducing the company's market opportunity [208]. Regulatory Environment - Azenosertib has received Fast Track Designation from the FDA for treating PROC patients who are positive for Cyclin E1 protein levels [30]. - The FDA regulates the drug approval process, requiring substantial time and financial resources for compliance [60]. - The FDA aims to review a standard New Drug Application (NDA) within ten months from the date of filing, with a typical review taking twelve months [72]. - The FDA may issue a Complete Response Letter if the NDA/BLA has deficiencies, requiring resubmission or withdrawal of the application [75]. - Approval of an NDA/BLA may include conditions such as changes to proposed labeling or the development of Risk Evaluation and Mitigation Strategies (REMS) [76]. - The FDA offers expedited programs like Fast Track and Breakthrough Therapy Designation to facilitate the review of products addressing serious conditions [80][81]. - The FDA requires approval of companion diagnostics at the same time as therapeutic products, which may complicate the approval process for new treatments [122]. - The FDA may deny PMA approval based on application deficiencies, which could delay the approval process significantly [128]. - The FDA requires pediatric assessments for most drugs under the Pediatric Research Equity Act (PREA) unless a deferral or waiver is granted [78]. - The FDA grants orphan drug designation to products intended for rare diseases affecting fewer than 200,000 individuals in the U.S. or those with no reasonable expectation of recovering development costs [87]. Financial Performance and Projections - Zentalis incurred net losses of $137.1 million and $165.9 million for the years ended December 31, 2025, and December 31, 2024, respectively, with an accumulated deficit of $1.2 billion as of December 31, 2025 [140]. - The company has no products approved for commercial sale and has not generated any revenue from product sales to date [138]. - The company expects to continue incurring significant expenses and increasing operating losses as it advances research and development efforts for azenosertib and future product candidates [141]. - The company anticipates substantial additional capital will be required to finance operations and support the commercialization of any approved product candidates [145]. - The company does not have any committed external funding sources and may need to seek additional financing through equity offerings or collaborations, which could dilute stockholder value [148]. - The company has incurred significant costs related to the development of a companion diagnostic and may face additional unanticipated costs in the future [145]. Strategic Focus and Governance - Zentalis completed a strategic restructuring in 2025, which included a workforce reduction of approximately 40% to support late-stage development for azenosertib [131]. - The company is primarily focused on the late-stage clinical development of azenosertib following a strategic restructuring in January 2025, but long-term success may depend on developing additional product candidates [157]. - The company aims to maintain a strong governance framework, including regular employee training on data privacy and cybersecurity [136]. - The company is committed to enhancing diversity and inclusivity within its workforce and has implemented various employee development opportunities [132]. Risks and Challenges - The regulatory approval process for azenosertib is lengthy and unpredictable, and failure to obtain approval would significantly harm the company's business [161]. - The company faces risks related to the timely completion of clinical trials and the successful commercialization of azenosertib, which are essential for generating revenue [152]. - Collaborators may not commit sufficient resources to the marketing and distribution of products, which could hinder commercialization efforts [158]. - The company may need additional capital to pursue further development or commercialization of product candidates if collaborations are terminated or not successful [155]. - Changes in manufacturing methods during product development could increase costs and delay clinical trials [210]. - Product liability risks could adversely affect the company's business and financial condition if sufficient insurance coverage is not obtained [211]. - Coverage and reimbursement from third-party payors are essential for the commercialization of product candidates [212]. - The reimbursement process is time-consuming and costly, with no guarantee of consistent coverage across payors [213]. - Third-party payors are increasingly challenging drug prices and may require discounts, impacting revenue [214]. - International operations face extensive price controls and regulations, potentially limiting revenue from product candidates [215]. Manufacturing and Supply Chain - The company currently relies on third-party contract manufacturing organizations (CMOs) for the production of product candidates, with no plans to establish its own manufacturing facilities [43]. - Clinical trial supplies for azenosertib are obtained from CMOs on a purchase order basis, with no long-term supply arrangements in place [44]. - Delays in developing a sustainable manufacturing process for companion diagnostics may hinder the timely commercialization of azenosertib and future product candidates [184].